Psyence Group Corporate Update
Highlights:
TORONTO, July 12, 2023 (GLOBE NEWSWIRE) — Psyence Group Inc. (CSE: PSYG | OTCQB:PSYGF) (“Psyence” or the “Company”) is pleased to provide the following corporate update on its strategic focus areas namely: Psyence Therapeutics and Psyence Production. The Psyence Group develops and provides innovative, safe, and effective psychedelic and nature-centered solutions for mental health and palliative care.
Related news for (PSYGF)
- Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial
- Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
- Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business
- Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study
- Psyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic Division